Acanthamoeba Keratitis
10
2
2
6
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 17/100
0.0%
0 terminated out of 10 trials
100.0%
+13.5% vs benchmark
30%
3 trials in Phase 3/4
50%
3 of 6 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 6 completed trials
Clinical Trials (10)
Parasitic Ulcer Treatment Trial
Parasitic Ulcer Treatment Trial Pilot
Retrospective Chart Review of Patients With Acanthamoeba Keratitis Who Have Received 0.8 mg/mL Polihexanide as Part of the "Medicines in Special Situations" (Medicamentos en Situaciones Especiales) Program in Spain.
Rose Bengal Electromagnetic Activation With Green Light for Infection Reduction
Retrospective Chart Review of Patients With Acanthamoeba Keratitis Who Have Received 0.8 mg/ml Polihexanide
Ultrahigh-resolution Optical Coherence Tomography Imaging of the Anterior Eye Segment Structures
Acanthamoeba and Artificial Intelligence
Polihexanide (PHMB) Eye Drops in Patients Affected by Acanthamoeba Keratitis
Safety and Tolerability of Preservative-free Polyhexamethylene Biguanide (PHMB) Ophthalmic Solution in Healthy Subjects
Retrospective Study of Acanthamoebic Keratitis During the Past 10 Years